Back to search

Article

Comprehensive Analysis of 177Lu-lilotomab Satetraxetan in Lymphoma Cell Lines: Implications for Precision Radioimmunotherapy and Combination Schemes

2025-05-14

Abstract excerpt

<title>Abstract</title> <p>Background: <sup>177</sup>Lu-lilotomab satetraxetan (Betalutin) is an anti-CD37 radioimmunoconjugate evaluated as single administration therapy for the treatment of patients with relapsed/refractory follicular lymphoma or diffuse large B-cell lymphoma (DLBCL). <sup>177</sup>Lu-lilotomab satetraxetan treatment is well-tolerated and shows consistent activity in most of the patients evalu...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
1268113d-5aef-58f4-8b27-57af53e2f88b
DOI
10.21203/rs.3.rs-6427224/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Comprehensive Analysis of 177Lu-lilotomab Satetraxetan in Lymphoma Cell Lines: Implications for Precision Radioimmunotherapy and Combination SchemesDOI 10.21203/rs.3.rs-6427224/v1
Comprehensive Analysis of <sup>177</sup> Lu-lilotomab Satetraxetan in Lymphoma Cell Lines: Implications for Precision Radioimmunotherapy and Combination SchemesSemantic proximity
GPR183 mediates the capacity of the novel CD47-CD19 bispecific antibody TG-1801 to heighten ublituximab-umbralisib (U2) anti-lymphoma activitySemantic proximity
PI3Kδ activation, IL6 over-expression, and CD37 loss cause resistance to the targeting of CD37-positive lymphomas with the antibody-drug conjugate naratuximab emtansineSemantic proximity
Front-line Chemo-immunotherapy with Nivolumab and Dose-Adjusted (DA) EPOCH in Peripheral T-cell Lymphoma: A Phase I TrialSemantic proximity
An overview on anti-tubulin agents for the treatment of lymphoma patientsSemantic proximity
Evaluation of RC48-ADC in combination with PRaG regimen: An open-label, prospective, multicentre study assessing efficacy and safety for advanced refractory HER2-expressing solid tumors (PRaG3.0 Study Protocol)Semantic proximity
Loss in MCL-1 function sensitizes non-Hodgkin’s lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199)Semantic proximity
Radio-immunotherapy by 188Re-antiCD20 and stable silencing of IGF-IR in Raji cells, new insight in treatment of lymphomaSemantic proximity
Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial.Semantic proximity
A general approach to reduce off-target radioactivity in vivo via Tetrazine-Knock-Out (TKO)Semantic proximity
High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibitionSemantic proximity
Specific Imaging of CD8+ T-Cell Dynamics with a Nanobody Radiotracer against Human CD8βSemantic proximity
Select a neighboring publication to make it the new centre.